The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
 
Robert M. Kraft
No Relationships to Disclose
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Jose Caetano Villasboas
Consulting or Advisory Role - Kite/Gilead (Inst); Regeneron (Inst)
 
N. Nora Bennani
No Relationships to Disclose
 
Yucai Wang
Consulting or Advisory Role - Loxo (Inst)
Research Funding - Genentech (Inst); Incyte (Inst); InnoCare (Inst); Novartis (Inst)
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
 
Gita Thanarajasingam
No Relationships to Disclose
 
David James Inwards
Research Funding - Acerta Pharma (Inst)
 
Luis F. Porrata
No Relationships to Disclose
 
Ivana N. M. Micallef
No Relationships to Disclose
 
Thomas E. Witzig
Consulting or Advisory Role - Abbvie/Genentech (Inst); ADC Therapeutics; Celgene (Inst); Cellectar; Epizyme; Incyte (Inst); Karyopharm Therapeutics; MorphoSys (Inst); Portola Pharmaceuticals; Seagen (Inst); Tessa Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Carrie A. Thompson
No Relationships to Disclose
 
Patrick B. Johnston
Consulting or Advisory Role - BTG
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Debiopharm Group; Genentech (Inst); Kite/Gilead; MorphoSys (Inst); Selvita
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)
 
Jonas Paludo
Research Funding - Verily (Inst)
Other Relationship - Jazz Pharmaceuticals (Inst)